Class I Histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Shen, Li ^a   Ciesielski, Michael ^a   Ramakrishnan, Swathi ^a   Miles, Kiersten M ^a   Ellis, Leigh ^a   Sotomayor, Paula ^a   Shrikant, Protul ^a   Fenstermaker, Robert ^a   Pili, Roberto ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTINOSTAT; GAMMA INTERFERON; INTERLEUKIN 2; STAT3 PROTEIN; SURVIVIN; TRANSCRIPTION FACTOR FOXP3; BENZAMIDE DERIVATIVE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (N (PYRIDIN 3 YLMETHOXYCARBONYL)AMINOMETHYL)BENZAMIDE; N-(2-AMINOPHENYL)-4-(N-(PYRIDIN-3-YLMETHOXYCARBONYL)AMINOMETHYL)BENZAMIDE; PYRIDINE DERIVATIVE; SUBUNIT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER MODEL; CASTRATION RESISTANT PROSTATE CANCER; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FOXP3 GENE; GENE; GENE EXPRESSION REGULATION; IMMUNOMODULATION; IN VITRO STUDY; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TARGET CELL; TRANSCRIPTION REGULATION; WESTERN BLOTTING; ACETYLATION; ANIMAL; CASTRATION; CD8+ T LYMPHOCYTE; DISEASE MODEL; DRUG EFFECT; GENETICS; HUMAN; IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY TUMOR; LYMPHOCYTE DEPLETION; METABOLISM; PATHOLOGY; PROSTATE TUMOR;

MURINAE; MUS;

ACETYLATION; ANIMALS; BENZAMIDES; CARCINOMA, RENAL CELL; CASTRATION; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; IMMUNITY; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-2; KIDNEY NEOPLASMS; LYMPHOCYTE DEPLETION; MALE; MICE; PROSTATIC NEOPLASMS; PYRIDINES; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY; VACCINES, SUBUNIT;

EID: 84856403025     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030815     Document Type: Article

References (51)

1. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, et al. (2006) CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177: 7398-7405.
2. Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM, et al. (2008) Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 14: 1032-1040.
3. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, et al. (2009) Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 69: 609-615.
4. Chen L, (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4: 336-347.
5. Shariat SF, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, et al. (2001) Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 19: 2856-2864.
6. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, et al. (2001) Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 193: 1285-1294.
7. Read S, Powrie F, (2001) CD4(+) regulatory T cells. Curr Opin Immunol 13: 644-649.
8. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, et al. (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756-2761.
9. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, et al. (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115: 3623-3633.
10. Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, et al. (2005) Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 11: 1238-1243.
11. Ahmadzadeh M, Rosenberg SA, (2006) IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107: 2409-2414.
12. Abrams JS, Rayner AA, Wiernik PH, Parkinson DR, Eisenberger M, et al. (1990) High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma. J Natl Cancer Inst 82: 1202-1206.
13. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, et al. (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338: 1272-1278.
14. Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ, (2005) Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 54: 369-377.
15. Antony PA, Restifo NP, (2002) Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy? J Immunother 25: 202-206.
16. Marks OA, Rifkind RA, Richon VM, Breslow R, Miller T, et al. (2001) Histone deacetylases and cancer: causes and therapies. Nature Rev Cancer 1: 194-202.
17. Johnstone RW, (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299.
18. Glozak MA, Sengupta N, Zhang X, Seto E, (2005) Acetylation and deacetylation of non-histone proteins. Gene 363: 15-23.
19. Gu W, Roeder RG, (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606.
20. Chen L, Meng S, Wang H, Bali P, Bai W, et al. (2005) Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther 4: 1311-1319.
21. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, et al. (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proceedings of the National Academy of Sciences of the United States of America 96: 4592-4597.
22. Hess-Stumpp H, Apetri E, Hoffmann J, (2005) MS-275, a potent orally active inhibitor of histone deacetylase, is efficacious in a wide range of experimental tumors; In vivo efficacy data. Proceedings of the American Association of Cancer Research 46: 607.
23. Jabion J, Wild J, Hamidi H, Khanna C, Kim CJ, et al. (2002) MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumoractivity against pediatric tumor. Cancer research 62: 6108-6115.
24. Qian DZ, Ren M, Wei Y, Wang X, van de Geijn F, et al. (2005) In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells. Prostate 64: 20-28.
25. Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, et al. (2007) Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res 13: 4538-4546.
26. Reddy P, Maeda Y, Hotary K, Liu C, Reznikov LL, et al. (2004) Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A 101: 3921-3926.
27. Brogdon JL, Xu Y, Szabo SJ, An S, Buxton F, et al. (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 109: 1123-1130.
28. Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, et al. (2000) Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol 165: 7017-7024.
29. Maeda T, Towatari M, Kosugi H, Saito H, (2000) Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 96: 3847-3856.
30. Tao R, de Zoeten EF, Ozkaynuk E, Chen C, Wang L, et al. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nature Medicine 13: 1299-1307.
31. Wang XF, Qian DZ, Ren M, (2005) epigenetic modulation of retinotic acid receptor b2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res 11: 3535-3542.
32. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, et al. (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59: 3128-3133.
33. Ciesielski MJ, Ahluwalia MS, Munich SA, Orton M, Barone T, et al. (2010) Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother 59: 1211-1221.
34. Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S, et al. (2004) Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol 171: 1855-1860.
35. Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Pili R, (2011) Development of a castrate resistant transplant tumor model of prostate cancer. Prostate.
36. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, et al. (2003) Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4: 223-238.
37. Yuan ZL, Guan YJ, Chatterjee D, Chin YE, (2005) Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307: 269-273.
38. Wang R, Cherukuri P, Luo J, (2005) Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J Biol Chem 280: 11528-11534.
39. Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, et al. (2001) Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 276: 45443-45455.
40. de Zoeten EF, Wang L, Sai H, Dillmann WH, Hancock WW, Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 138: 583-594.
41. Duong V, Bret C, Altucci L, Mai A, Duraffourd C, et al. (2008) Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res 6: 1908-1919.
42. Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, et al. (2008) MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7: 759-768.
43. Chen X, Oppenheim JJ, Howard OM, (2005) BALB/c mice have more CD4+CD25+ T regulatory cells and show greater susceptibility to suppression of their CD4+CD25- responder T cells than C57BL/6 mice. J Leukoc Biol 78: 114-121.
44. Sanderson L, Taylor GW, Aboagye EO, Alao JP, Latigo JR, et al. (2004) Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice. Drug Metab Dispos 32: 1132-1138.
45. van Loosdregt J, Vercoulen Y, Guichelaar T, Gent YY, Beekman JM, et al. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood 115: 965-974.
46. Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, et al. (2006) Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24: 1169-1177.
47. Fontenot JD, Gavin MA, Rudensky AY, (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330-336.
48. Doganci A, Eigenbrod T, Krug N, De Sanctis GT, Hausding M, et al. (2005) The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest 115: 313-325.
49. Huber M, Steinwald V, Guralnik A, Brustle A, Kleemann P, et al. (2008) IL-27 inhibits the development of regulatory T cells via STAT3. Int Immunol 20: 223-234.
50. Rudra D, Egawa T, Chong MM, Treuting P, Littman DR, et al. (2009) Runx-CBFbeta complexes control expression of the transcription factor Foxp3 in regulatory T cells. Nat Immunol 10: 1170-1177.
51. Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, et al. (2006) Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 12: 634-642.